Patient Last Name:	First:	DOB:
Updated Contact Information:		
Address:		Phone:
This patient is currently under your care for TB: \Box If	not, complete on Section 1 bel	low. If so, skip to Section 2(a).
Section 1		
What was the date you last saw the patient?		
, ,	l Yes □ No	□ Unknown
If you are no longer the patient's physician, please prov	ride the name and phone numb	per of the patient's current physician, if
known:		
Name:		Phone:
Thank you for your assistance!		
Section 2(a)		
Check here if your patient routinely attends scheduled of	clinical appointments: □	
Check here if your patient's progress has been monitored	ed by serial chest x-rays: □	
If so, latest CXR Date:	Finding: □ Stable	☐ Improving ☐ Worsening
For TB confirmed by culture, check here if additional b	acteriology has been collected	1: □
If so, complete "Latest Bacteriology" below:		
Latest Bacteriology	Collection Date:	
Source: ☐ Sputum ☐ Gastric Aspirate	Smear	If Positive, Quantity:
□ Pleural Fluid □ Urine □ Spinal Fluid	☐ Positive AFB	□ +/- □ 3+
□ Lung Tissue □ Blood □ Bronchial Washing	g □ Negative	□ 1+ □ 4+
☐ Lymph Node ☐ Other:	_ □ Not Done	□ 2+ □ Not Reported
Culture: \square M.tb \square Mycobacterium Other Than	TB □ Negative	☐ Other, specify:
If the latest bacteriology is negative on culture, date of	collection of any previous neg	gative culture:
Check here if anti-TB therapy has been completed: □	Date Completed:	
If your patient is still on anti-TB therapy, please comple	ete Section 2(b). If not, the for	rm is complete. Thank you for your
assistance!		
Section 2(b)		
Check here if your patient is currently taking anti-TB m	nedications as prescribed: □	If not, read ** below.
Notes on Patient's Adherence to Treatment:		
Current Therapy		
Dose/Frequency	Dose/Frequency	Dose/Frequency
□ Isoniazid □ Rifampin		□ Rifabutin
□ Pyrazinamide		☐ Streptomycin
☐ Other, specify:		
What date do you anticipate discontinuing anti-TB med	ications?	Thank you for your assistance!
** The Virginia Department of Health and the Centers	for Disease Control & Prevent	tion recommend directly observed therapy (D
as the Standard of Care for all patients with pulmonar		•
observes their ingestion on a daily or twice weekly basi		_
Guarante Guarante de Control de C		
Completed by:	Date	a·